Harvard Apparatus Regenerative Tech Inc  

(Public, NASDAQ:HART)   Watch this stock  
Find more results for JOHN F. MCNAUGHTON
-0.01 (-0.56%)
Real-time:   3:17PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.71 - 1.85
52 week 0.53 - 4.44
Open 1.85
Vol / Avg. 508,726.00/1.65M
Mkt cap 24.80M
P/E     -
Div/yield     -
EPS -1.29
Shares 13.45M
Beta     -
Inst. own 24%
Nov 12, 2015
Q3 2015 Harvard Apparatus Regenerative Technology Inc Earnings Call - Webcast
Nov 12, 2015
Q3 2015 Harvard Apparatus Regenerative Technology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -6194.60% -11893.55%
Operating margin -6194.60% -11889.25%
EBITD margin - -11498.92%
Return on average assets -85.65% -99.34%
Return on average equity -118.33% -105.03%
Employees 24 -
CDP Score - -


84 October Hill Rd Ste 11
HOLLISTON, MA 01746-1371
United States - Map
+1-774-2337300 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company making regenerated organs for transplant. The Company's product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea (windpipe). The HART-Trachea comprises the patient's own bone marrow cells seeded on the Company's InBreath porous plastic scaffold in its InBreath organ bioreactor. Its HART-Trachea addresses both of the challenges to trachea transplant, such as the shortage of suitable donor tracheas and the risk and expense of lifelong anti-rejection drug therapy. The Company has received orphan drug designation from the United States Food and Drug Administration (FDA) for the HART-Trachea in the United States market. The Company is engaged in pre-clinical development of its HART-Trachea.

Officers and directors

John F. Kennedy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
James J. McGorry President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Thomas McNaughton Jr. Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Saverio La Francesca M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
David M. Green Director
Age: 50
Bio & Compensation  - Reuters
John J. Canepa Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas H. Robinson Independent Director
Age: 56
Bio & Compensation  - Reuters